BACKGROUND AND OBJECTIVE: It has been suggested that inhibition of poly (ADP-ribose) polymerase-1 (PARP-1), either pharmacologically or by a gene knockout provides significant protection against systemic or tissue inflammation in animal models. The aim of this study was to analyze the association of the PARP-1 Val762Ala polymorphism, which has beenreported to be associated with decreased enzymatic activity, in Turkish patients with adult asthma. METHODS: A total of 112 subjects with stable asthma and 180 normal controls from the same geographic region were studied and polymerase chain reaction-based restriction analysis was used to identify Val762Ala polymorphism of the PARP-1. RESULTS: In univariate analysis, PARP-1 762 AA genotype conferred a 3.4 fold reduction in risk (OR = 0.297, 95% CI = 0.105-0.813; P = 0.014), while heterozygous VA genotype conferred an even greater level of protection (OR = 0.06; 95%CI, 0.026-0.14; P < 10(-6)). In addition, wild type PARP-1 762 V allele had 5 times the risk of developing asthma than those without the allele (OR 0.199, CI 0.118-0.334, P = 10(-6)). CONCLUSIONS: These findings suggest that PARP-1 V762A variants may be one of the factors participating in protection or susceptibility to asthma in our population.
BACKGROUND AND OBJECTIVE: It has been suggested that inhibition of poly (ADP-ribose) polymerase-1 (PARP-1), either pharmacologically or by a gene knockout provides significant protection against systemic or tissue inflammation in animal models. The aim of this study was to analyze the association of the PARP-1 Val762Ala polymorphism, which has beenreported to be associated with decreased enzymatic activity, in Turkish patients with adult asthma. METHODS: A total of 112 subjects with stable asthma and 180 normal controls from the same geographic region were studied and polymerase chain reaction-based restriction analysis was used to identify Val762Ala polymorphism of the PARP-1. RESULTS: In univariate analysis, PARP-1 762 AA genotype conferred a 3.4 fold reduction in risk (OR = 0.297, 95% CI = 0.105-0.813; P = 0.014), while heterozygous VA genotype conferred an even greater level of protection (OR = 0.06; 95%CI, 0.026-0.14; P < 10(-6)). In addition, wild type PARP-1 762 V allele had 5 times the risk of developing asthma than those without the allele (OR 0.199, CI 0.118-0.334, P = 10(-6)). CONCLUSIONS: These findings suggest that PARP-1V762A variants may be one of the factors participating in protection or susceptibility to asthma in our population.
Authors: R Datta; A S Naura; M Zerfaoui; Y Errami; M Oumouna; H Kim; J Ju; V P Ronchi; A L Haas; A H Boulares Journal: Allergy Date: 2011-01-28 Impact factor: 13.146
Authors: Mohamed A Ghonim; Kusma Pyakurel; Salome V Ibba; Amir A Al-Khami; Jeffrey Wang; Paulo Rodriguez; Hamada F Rady; Ali H El-Bahrawy; Matthew R Lammi; Moselhy S Mansy; Kamel Al-Ghareeb; Alistair Ramsay; Augusto Ochoa; Amarjit S Naura; A Hamid Boulares Journal: J Transl Med Date: 2015-07-14 Impact factor: 5.531